NOT FDA-APPROVED

IGF-DES (des(1-3) IGF-1)

A truncated IGF-1, three amino acids shorter than the native molecule. Even less affinity for IGF binding proteins than LR3, more potent at the receptor, but with a much shorter window of action. The bodybuilding world's site-injection IGF.

The 30-second read

IGF-DES (des(1-3) IGF-1) is native human IGF-1 with the first three amino acids removed. Those amino acids are the part of the IGF-1 molecule that binds tightest to the IGF binding proteins (IGFBPs). Without them, IGF-DES barely binds IGFBPs at all, it stays free in the bloodstream and reaches receptors more efficiently. Per molecule, it's reported to be roughly 5–10x more potent at the IGF-1 receptor than native IGF-1. Compared with IGF-1 LR3, IGF-DES is more potent at the receptor but has a much shorter half-life, which is why bodybuilders historically used it for site-specific intramuscular injection close to a worked muscle. Not FDA-approved. Same cancer-biology considerations as LR3 apply, plus the same hypoglycemia risk.

Why this peptide is on people's radar

IGF-DES sits in the same conceptual space as IGF-1 LR3, a modified IGF-1 designed to evade the IGF binding protein system that normally clears native IGF-1 from circulation. Where LR3 adds amino acids (an N-terminal extension) to disrupt IGFBP binding, IGF-DES does the opposite: it removes the first three amino acids, which happen to be the dominant IGFBP-binding region of the native molecule. Result: IGFBP affinity drops dramatically, more of the peptide stays free and bioavailable, and per molecule it's reported to be 5 to 10 times more potent at the IGF-1 receptor than native IGF-1.

The trade-off versus LR3 is duration. LR3's modifications produce a half-life around 20 hours. IGF-DES's truncation produces a peptide that's more potent at the receptor but cleared from circulation much faster, typically minutes to a couple of hours. That short window is why bodybuilders historically used IGF-DES for site-specific intramuscular injection close to a target muscle: the theory was that injecting near the worked muscle produced a localized hypertrophy effect before the peptide cleared systemically. Whether that localized-effect claim holds up is much less rigorous than the marketing suggested.

For context: IGF-DES has been used in research as a tool for studying IGF-1-receptor biology without the IGFBP-dynamics confounds that complicate native-IGF-1 studies. The pharmacology is genuinely useful for that. Translating the receptor-potency advantage into clinical applications is where the gap from "research tool" to "useful drug" hasn't been bridged.

What people are usually trying to do with it

People exploring IGF-DES are usually focused on:

Site-specific muscle hypertrophy via intramuscular injection close to a worked muscle
Maximum receptor potency on a per-molecule basis
Acute anabolic effect tied to specific training sessions
An alternative to IGF-1 LR3 for users who specifically want the shorter window of action

What the science actually shows

Plain-English summary:

Higher receptor potency than native IGF-1

Multiple studies confirm IGF-DES has 5 to 10x higher potency at the IGF-1 receptor than native IGF-1 at equivalent concentrations. The IGFBP-evasion-via-truncation mechanism works as designed.1

Shorter half-life than LR3

IGF-DES's plasma half-life is on the order of minutes to a few hours, much shorter than LR3's ~20 hours. This is the essential pharmacological trade-off between the two analogs.2

Anabolic effects in animal models

Animal studies report increased muscle hypertrophy, satellite cell activation, and improved lean-mass markers with IGF-DES administration, consistent with sustained IGF-1-receptor activation.3

Localized hypertrophy claims

The "site injection produces local muscle growth" framing is bodybuilding-community-derived. Some local effect at the injection site is plausible given the short half-life, but rigorous evidence that site injection produces meaningfully better localized hypertrophy than systemic injection is thin.

What hasn't been demonstrated

FDA approval for any indication. Long-term safety in healthy adults. That site-specific injection produces reliably localized effects beyond what systemic IGF-1 receptor activation would produce. That IGF-DES outperforms LR3 in real-world muscle-growth outcomes.

The honest read

What's solid:

The pharmacology is well-characterized. IGF-DES does what its design predicts at the molecular level. As a research tool for studying IGF-1-receptor biology, it has a defined role.

What's still unproven:

Most of the bodybuilding-community use case. Site-injection localized hypertrophy claims are mostly anecdotal. Whether the per-molecule potency advantage translates into better real-world outcomes than LR3 produces. Long-term safety with chronic use.

What's a real concern:

Same as IGF-1 LR3, sustained or repeated free-IGF-1 exposure has theoretical implications for cancer biology that are real, well-documented in epidemiology, and not addressed by short-half-life dosing. The shorter window per dose doesn't eliminate the cumulative-exposure question.

What's hyped beyond the evidence:

"Site injection grows muscle locally" framings. The pharmacology is real; the localized-hypertrophy translation isn't well-supported. "5–10x more potent than native IGF-1 therefore better" overstates what receptor potency means in real-world bodybuilding outcomes.

Things to know if you're looking into it

Compared to LR3: more potent at the receptor per molecule, much shorter half-life. LR3 is the more common modern choice for systemic anabolic use; IGF-DES is the more common choice for site-injection bodybuilding protocols.
Site-injection theory vs evidence: the localized-hypertrophy claim is mostly anecdotal. Some local effect at the injection site is plausible, but a substantial portion of the dose still enters circulation.
Cancer-biology concern is the same as LR3: personal or strong family history of breast, prostate, colorectal, or other hormonally-driven cancers is a meaningful contraindication.
Hypoglycemia risk: like all IGF-1 analogs, can lower blood glucose. Eat carbs around dosing as the standard mitigation.
Athlete bans: IGF-1 and its analogs are on the WADA banned list. Competitive athletes will test positive.
Regulatory status: not FDA-approved. Not currently on the FDA Category 2 list as of 2026.
Specific dosing protocols, mechanism, and the full reference list: all in the "Want to go deeper?" section below.

What people often ask

How is IGF-DES different from IGF-1 LR3?

Different IGFBP-evasion strategy. LR3 adds amino acids (extension) to disrupt IGFBP binding. IGF-DES removes the first three amino acids (truncation). LR3 has a longer half-life (~20 hours). IGF-DES is more potent per molecule at the receptor but has a much shorter half-life (minutes to hours).

What does "des(1-3)" mean?

"des" is the chemistry shorthand for "missing." des(1-3) IGF-1 means IGF-1 missing amino acids 1, 2, and 3, the first three residues of the molecule. Those happen to be the part that binds IGFBPs hardest, so removing them dramatically reduces IGFBP binding.

Does site injection actually work locally?

Some local effect at the injection site is biologically plausible given the short half-life. Whether it produces meaningfully better localized muscle growth than a systemic dose would isn't rigorously established. Bodybuilding lore is more confident about this than the data supports.

Is IGF-DES safer than LR3?

Different pharmacology, similar conceptual risks. The shorter half-life means less duration of receptor activation per dose. But the cancer-biology concern is about cumulative IGF-1 receptor activation over time, which depends on how often you dose, not just per-dose duration. Frequent site-injection IGF-DES isn't necessarily safer than LR3 in that frame.

Is it FDA-approved?

No. Not approved for any indication. Not currently on the FDA Category 2 list.

Can it cause hypoglycemia?

Yes. Like all IGF-1 analogs, has insulin-like effects on glucose disposal. Eating carbs around dosing is the standard mitigation. Effects are typically more acute than with LR3 because of the shorter half-life.

Will I test positive on a drug test?

Yes. IGF-1 and its analogs are on the WADA banned list. Competitive athletes will test positive.

FDA and regulatory status

Status as of May 5, 2026: Not FDA-approved for any medical indication. Not currently on the FDA Category 2 list. On the World Anti-Doping Agency Prohibited List. Status updates land here when they happen.

Want to go deeper? Mechanism, IGFBP-binding biology, dosing, side-effect profile, and references.

Background

IGF-DES (des(1-3) IGF-1) is a truncated analog of native human IGF-1, missing amino acids 1, 2, and 3 from the N-terminus. The truncation removes the dominant IGFBP-binding region of the molecule, dramatically reducing affinity for the IGF binding proteins. Used as a research tool for studying IGF-1-receptor biology and in bodybuilding contexts for muscle hypertrophy.

Mechanism of action

IGF-1 receptor activation

Like native IGF-1 and IGF-1 LR3, IGF-DES binds the IGF-1 receptor (IGF1R) and triggers the same downstream signaling cascades. PI3K-Akt-mTOR for cell growth and protein synthesis, MAPK for proliferation.

IGFBP evasion via truncation

The first three amino acids of native IGF-1 are part of the dominant IGFBP-binding interface. Removing them drops IGFBP affinity dramatically, leaving IGF-DES essentially free in circulation. Receptor potency on a per-molecule basis is reported as 5 to 10x higher than native IGF-1.

Half-life

Plasma half-life is on the order of minutes to a few hours, much shorter than LR3's ~20 hours. This pharmacological difference is why the two analogs have different use-case profiles.

Commonly studied dosing protocols

These are not recommendations. Always consult a licensed healthcare provider before any clinical decision. IGF-DES carries the same cancer-biology and hypoglycemia considerations as IGF-1 LR3.

Site injection (research-community range): 50 to 150 mcg per dose, intramuscular, near the target muscle, often timed post-workout.

Subcutaneous (research-community range): 50 to 100 mcg per dose, often timed post-workout.

Treatment duration: typical research-community cycles are 4 to 6 weeks. Long-term continuous use raises the cumulative IGF-1-exposure question.

Side effects and safety profile

Reported in research-community use:

Hypoglycemia, symptoms typically more acute than with LR3 due to shorter half-life
Injection-site reactions (mild, sometimes more notable with intramuscular site injection)
Mild fatigue or lethargy (uncommon)
Edema or fluid retention (uncommon, dose-dependent)

Serious theoretical concerns: same as IGF-1 LR3. Cancer biology relationship via cumulative IGF-1 receptor activation. Acromegaly-like effects with sustained high-dose use.

References

Forbes BE, Hartfield PJ, McNeil KA, et al. (1988). "Characteristics of binding of insulin-like growth factor (IGF)-I and IGF-II analogues to the type 1 IGF receptor determined by BIAcore analysis." Eur J Biochem, 269(3), 961–968. PubMed
Tomas FM, Knowles SE, Owens PC, et al. (1991). "Increased weight gain, nitrogen retention and muscle protein synthesis following treatment of diabetic rats with insulin-like growth factor (IGF)-I and des(1-3)IGF-I." Biochem J, 276(Pt 2), 547–554. PubMed
Bagley CJ, May BL, Szabo L, et al. (1989). "A key functional role for the insulin-like growth factor 1 N-terminal pentapeptide." Biochem J, 259(3), 665–671. PubMed
Renehan AG, Zwahlen M, Minder C, et al. (2004). "Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis." The Lancet, 363(9418), 1346–1353. PubMed

For educational and research purposes only. This is not medical advice. IGF-DES is not FDA-approved. Same cancer-biology and hypoglycemia considerations as IGF-1 LR3 apply. Personal or strong family history of hormonally-driven cancers is a meaningful contraindication. Consult a licensed healthcare provider before considering any peptide. PeptideLibraryHub is independent and does not sell peptides or accept money from anyone who does.